Table 1.
Demographic and clinicopathological characteristics of patients with T1–2N0M0 breast cancer.
| Variables | All patients (%) | Overall death (%) | ||
| N | 161966 | 10567 | ||
| Age, y | ||||
| ≤45 | 15545 | 9.6 | 455 | 4.3 |
| 45–65 | 78355 | 48.4 | 2347 | 22.2 |
| 65–85 | 61761 | 38.1 | 5529 | 52.3 |
| >85 | 6305 | 3.9 | 2236 | 21.2 |
| Race | ||||
| White | 130709 | 80.7 | 8718 | 82.5 |
| Black | 15754 | 9.7 | 1298 | 12.3 |
| Other | 15503 | 9.6 | 551 | 5.2 |
| Year at diagnosis | ||||
| 2010–2012 | 76560 | 47.3 | 7581 | 71.7 |
| 2013–2016 | 85406 | 52.7 | 2986 | 28.3 |
| Grade | ||||
| Well | 46953 | 29.0 | 2409 | 22.8 |
| Moderately | 71565 | 44.2 | 4410 | 41.7 |
| Poorly | 43116 | 26.6 | 3705 | 35.1 |
| Undifferentiated | 332 | 0.2 | 43 | 0.4 |
| T stage | ||||
| T1 | 120985 | 74.7 | 6286 | 59.5 |
| T2 | 40981 | 25.3 | 4281 | 40.5 |
| Molecular type | ||||
| HR+/HER2+ | 14873 | 9.2 | 838 | 7.9 |
| HR−/HER2+ | 5577 | 3.4 | 383 | 3.6 |
| HR+/HER2− | 124540 | 76.9 | 7522 | 71.2 |
| HR−/HER2− | 16976 | 10.5 | 1824 | 17.3 |